DrugDashboards

Carbidopa and Levodopa

Carbidopa and Levodopa · CARBIDOPA 23.75 mg/1; LEVODOPA 95 mg/1 · Capsule, Extended Release · Oral · Remedyrepack Inc.

NDC 70518-4618-00 · 50 POUCH in 1 BOX / 1 CAPSULE, EXTENDED RELEASE in 1 POUCH · NDA AUTHORIZED GENERIC · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 70710-2139-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$3.58per unit
middle half $2.91$3.69 · 104 plans · Apr 1, 2026
Est. net of rebates
≈ $3.58
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
2%of plans cover it
tier 4 · prior auth 0% · step therapy 52% · qty limit 53%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for carbidopa and levodopa (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA203312
TE code
Approval date
Jan 7, 2015
Patents / exclusivity
32 patents, 0 exclusivities
TypeNumber / codeExpires
patent9089607Dec 26, 2028
patent9089607Dec 26, 2028
patent8377474Dec 26, 2028
patent8377474Dec 26, 2028
patent8377474Dec 26, 2028
patent8377474Dec 26, 2028
patent8454998Dec 26, 2028
patent8454998Dec 26, 2028
patent8454998Dec 26, 2028
patent8454998Dec 26, 2028
patent8557283Dec 26, 2028
patent9901640Dec 26, 2028

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Carbidopa and Levodopa (Capsule, Extended Release)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals LLCLEVODOPA 95 mg/1; CARBIDOPA HYDRATE 23.75 mg/1Aug 26, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 35 mg/1; LEVODOPA 140 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 52.5 mg/1; LEVODOPA 210 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 70 mg/1; LEVODOPA 280 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 87.5 mg/1; LEVODOPA 350 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLEVODOPA 145 mg/1; CARBIDOPA HYDRATE 36.25 mg/1Aug 26, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLEVODOPA 195 mg/1; CARBIDOPA HYDRATE 48.75 mg/1Aug 26, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLEVODOPA 245 mg/1; CARBIDOPA HYDRATE 61.25 mg/1Aug 26, 2026Sep 2, 2026
Remedyrepack Inc.CARBIDOPA 48.75 mg/1; LEVODOPA 195 mg/1Jul 15, 2026Sep 2, 2026
Remedyrepack Inc.CARBIDOPA 23.75 mg/1; LEVODOPA 95 mg/1Jul 15, 2026Sep 2, 2026
Remedyrepack Inc.CARBIDOPA 36.25 mg/1; LEVODOPA 145 mg/1Jul 15, 2026Sep 2, 2026
Remedyrepack Inc.CARBIDOPA 61.25 mg/1; LEVODOPA 245 mg/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.CARBIDOPA 61.25 mg/1; LEVODOPA 245 mg/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.CARBIDOPA 48.75 mg/1; LEVODOPA 195 mg/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.CARBIDOPA 23.75 mg/1; LEVODOPA 95 mg/1Jul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.CARBIDOPA 36.25 mg/1; LEVODOPA 145 mg/1Jul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals LLCLEVODOPA 48.75 mg/1; CARBIDOPA HYDRATE 195 mg/1Jul 22, 2026Aug 19, 2026
Amneal Pharmaceuticals LLCLEVODOPA 61.25 mg/1; CARBIDOPA HYDRATE 245 mg/1Jul 22, 2026Aug 19, 2026
Amneal Pharmaceuticals LLCLEVODOPA 23.75 mg/1; CARBIDOPA HYDRATE 95 mg/1Jul 22, 2026Aug 19, 2026
Amneal Pharmaceuticals LLCLEVODOPA 36.25 mg/1; CARBIDOPA HYDRATE 145 mg/1Jul 22, 2026Aug 19, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 23.75 mg/1; LEVODOPA 95 mg/1Jul 15, 2026Jul 15, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 61.25 mg/1; LEVODOPA 245 mg/1Jul 15, 2026Jul 15, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 48.75 mg/1; LEVODOPA 195 mg/1Jul 15, 2026Jul 15, 2026
Amneal Pharmaceuticals LLCCARBIDOPA HYDRATE 36.25 mg/1; LEVODOPA 145 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Carbidopa and Levodopa — NDC 70518-4618-00," retrieved September 3, 2026, https://drugdashboards.com/drug/70518461800.

Free to cite with attribution — see how the data is put together.